Real‐World Outcomes After Dupilumab Initiation for Pediatric Chronic Rhinosinusitis with Nasal Polyps
Otolaryngology–Head and Neck Surgery · 2026-11-17
DOI: 10.1002/ohn.70523 ↗At a glance
Journal article in Otolaryngology–Head and Neck Surgery, published online on 2026-11-17. Written by Maaz S Haji and 5 co-authors. Institution: Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, Illinois, USA. 17 references.
Abstract (original language)
Objective
To evaluate whether dupilumab initiation is associated with reduced short‐term flare burden, healthcare utilization, and surgical escalation in pediatric patients with chronic rhinosinusitis with nasal polyps (CRSwNP). Study Design Retrospective cohort study.
Setting
TriNetX United States Collaborative Network.
Methods
Patients aged ≤18 years with chronic rhinosinusitis with nasal polyps were identified between January 1, 2015, and December 31, 2024. Dupilumab‐treated patients were indexed at treatment initiation and propensity score‐matched 1:1 to nondupilumab controls indexed at a systemic corticosteroid burst based on asthma, atopic dermatitis, allergic rhinitis, and prior endoscopic sinus surgery. Outcomes within 12 months were compared using risk ratios.
Results
In 442 matched patients (221 per cohort), dupilumab‐treated patients had lower rates of acute sinusitis (12/221 [5.4%] vs 31/221 [14.0%]; risk ratio [RR] 0.39; 95% CI: 0.20‐0.73; P = .002), systemic corticosteroid bursts (80/221 [36.2%] vs 101/221 [45.7%]; RR 0.79; 95% CI: 0.63‐0.99; P = .042), and functional endoscopic sinus surgery (19/221 [8.6%] vs 38/221 [17.2%]; RR 0.50; 95% CI: 0.30‐0.84; P = .007). Nasal polyp diagnoses were more frequently documented in the dupilumab‐treated cohort (148/221 [67.0%] vs 95/221 [43.0%]; P < .0001), while emergency department visits (16/221 [7.2%] vs 27/221 [12.2%]; P = .078) and inpatient admissions (12/221 [5.4%] vs 16/221 [7.2%]; P = .435) were similar between cohorts.
Conclusion
These findings suggest that dupilumab may be a steroid‐sparing and surgery‐sparing option in pediatric CRSwNP.
Subjects
Author keywords
Authors and institutions
- Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, Illinois, USA.
- Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York, USA.
- Department of Otolaryngology, University of Missouri School of Medicine, Columbia, Missouri, USA.
ORCID profiles: Maaz S Haji, Abraham A Kassem, Alexa F Ibrahim, Paula V G Navarro, Deepthi Akella, Michele M Carr
Cite
APA
Haji, M. S., Kassem, A. A., Ibrahim, A. F., Navarro, P. V. G., Akella, D., & Carr, M. M. (2026). Real‐World Outcomes After Dupilumab Initiation for Pediatric Chronic Rhinosinusitis with Nasal Polyps. Otolaryngology–Head and Neck Surgery. https://doi.org/10.1002/ohn.70523
Vancouver
Haji MS, Kassem AA, Ibrahim AF, Navarro PVG, Akella D, Carr MM. Real‐World Outcomes After Dupilumab Initiation for Pediatric Chronic Rhinosinusitis with Nasal Polyps. Otolaryngology–Head and Neck Surgery. 2026. doi:10.1002/ohn.70523
BibTeX
@article{Haji2026,
author = {Haji, Maaz S and Kassem, Abraham A and Ibrahim, Alexa F and Navarro, Paula V G and Akella, Deepthi and Carr, Michele M},
title = {Real‐World Outcomes After Dupilumab Initiation for Pediatric Chronic Rhinosinusitis with Nasal Polyps},
journal = {Otolaryngology–Head and Neck Surgery},
year = {2026},
doi = {10.1002/ohn.70523}
}
EUVIMED